Target Points in Trastuzumab Resistance | Zendy

Sahar Shojaei | Zendy; Mossa Gardaneh | Zendy; A Rahimi Shamabadi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Target Points in Trastuzumab Resistance

Author(s) -

Sahar Shojaei,

Mossa Gardaneh,

A Rahimi Shamabadi

Publication year - 2012

Publication title -

international journal of breast cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.552

H-Index - 15

eISSN - 2090-3170

pISSN - 2090-3189

DOI - 10.1155/2012/761917

Subject(s) - trastuzumab , medicine , effector , breast cancer , cancer research , human epidermal growth factor receptor 2 , cancer , receptor , carcinogenesis , oncology , signal transduction , immunology , biology , microbiology and biotechnology

Epidermal growth factor (EGF) family of receptors is involved in cell growth and differentiation. The human EGF2 (HER2) lacks natural ligands, and correlation between HER2 levels and carcinogenesis makes the receptor an ideal candidate for targeted therapy in breast cancer. Trastuzumab is a humanized antibody applied against HER2-positive breast tumors in clinic. Metastatic tumors respond well to trastuzumab therapy for the first year, but development of antibody resistance helps the tumors to regrow allowing the disease to progress. Trastuzumab resistance is shaped via a range of intracellular signaling pathways that are interconnected and share in key effector molecules. Identification of a common node central to these resistance pathways could provide an ultimate solution for trastuzumab resistance in breast and other cancers.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research